Baxter International Inc vs Byrna Technologies Inc — how do they compare? Baxter International Inc trades at $21.78 (market cap $11.26B), while Byrna Technologies Inc trades at $3.55 (market cap $80.33M). The key difference: Baxter International Inc is far larger — about 140.2× Byrna Technologies Inc's market cap, and Baxter International Inc pays a 0.92% dividend while Byrna Technologies Inc pays none. Which is the better fit depends on your goals.
| BAX | BYRN | |
|---|---|---|
Market Cap | $11.26B | $80.33M |
Sector | Health | Technology |
52-Week High | $29.22 | $27.63 |
52-Week Low | $15.80 | $3.54 |
Enterprise Value | $18.93B | $71.94M |
Dividend Yield | 0.92% | — |
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
BYRN trades at $3.82, down 1.16% today, with a bearish technical signal from moving averages. Recent Q2 2026 results showed a significant miss with a $0.44 EPS loss versus -$0.10 expected, amid a 42.5% revenue decline. The company is undergoing a marketing reset and acquired HERO Defense Systems to expand its product portfolio. Net income margin turned negative at -3.39% for 2026, though gross margin remains strong at 52.51%.
Outlook is cautious due to execution risks in sales turnaround efforts. Analyst consensus is bullish with 71% buy ratings, but near-term challenges in e-commerce traffic and conversion pose headwinds. The stock's valuation appears reasonable with P/S of 0.76, but profitability concerns and ongoing legal investigations present substantial risks for investors.
Trailing returns across standard periods
Latest headlines on both assets
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →